Logo 1 Logo 2

Clinical Trial Details

Trial ID: L6671
Source ID: NCT02205528
Associated Drug: Liraglutide
Title: A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Diabetes|Diabetes Mellitus Type 2
Interventions: DRUG: Liraglutide|DRUG: Metformin|DRUG: Placebo|DRUG: NNC0090-2746
Outcome Measures: Primary: Change in HbA1c, Day 1; Week 8 | Secondary: Change in body weight, Day 1; Week 8; Week 12|Percent change in body weight, Day 1; Week 8; Week 12|Change in fasting plasma glucose (FPG), Day 1; Week 12|Change in post-prandial plasma glucose level, Day -7; Week 12|Change in post-prandial insulin level, Day -7; Week 12|Change in post-prandial C-peptide level, Day -7; Week 12|Change in beta-cell function, According to the Homeostasis Model Assessment (HOMA) score, Day 1; Week 12|Incidence of treatment-emergent adverse events, Day 1; Week 18|Change in percent HbA1c, Day 1; Week 12
Sponsor/Collaborators: Sponsor: Novo Nordisk A/S
Gender: ALL
Age: CHILD, ADULT, OLDER_ADULT
Phases: PHASE2
Enrollment: 108
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
Start Date: 2014-08-18
Completion Date: 2015-09-15
Results First Posted:
Last Update Posted: 2020-07-21
Locations: Novo Nordisk Investigational Site, Chino, California, 91710, United States|Novo Nordisk Investigational Site, Hawaiian Gardens, California, 90716, United States|Novo Nordisk Investigational Site, Los Angeles, California, 90057, United States|Novo Nordisk Investigational Site, Spring Valley, California, 91978, United States|Novo Nordisk Investigational Site, Hialeah, Florida, 33012, United States|Novo Nordisk Investigational Site, Port Orange, Florida, 32127, United States|Novo Nordisk Investigational Site, Sanford, Florida, 32771, United States|Novo Nordisk Investigational Site, Chicago, Illinois, 60607, United States|Novo Nordisk Investigational Site, Evanston, Illinois, 60201, United States|Novo Nordisk Investigational Site, Oxon Hill, Maryland, 20745, United States|Novo Nordisk Investigational Site, Berlin, New Jersey, 08009, United States|Novo Nordisk Investigational Site, Albuquerque, New Mexico, 87102, United States|Novo Nordisk Investigational Site, Greensboro, North Carolina, 27408, United States|Novo Nordisk Investigational Site, Cincinnati, Ohio, 45227, United States|Novo Nordisk Investigational Site, Tulsa, Oklahoma, 74136, United States|Novo Nordisk Investigational Site, Eugene, Oregon, 97404, United States|Novo Nordisk Investigational Site, Knoxville, Tennessee, 37920, United States|Novo Nordisk Investigational Site, Corpus Christi, Texas, 78404, United States|Novo Nordisk Investigational Site, Houston, Texas, 77074, United States|Novo Nordisk Investigational Site, Manassas, Virginia, 20110, United States
URL: https://clinicaltrials.gov/show/NCT02205528

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress
D089 Metformin small molecule DB00331 Details